Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays
Supports Earlier Data Showing AUG-3387 Binds Strongly to Delta Variant in Addition to Wild-Type Spike Protein and Other Variants of Concern
Catalent Selected as Contract Drug Manufacturing Organization (CDMO) for AUG-3387
Scale-up Manufacturing for AUG-3387 Proceeding Rapidly; Early Batches Show Promising Results
https://finance.yahoo.com/news/augmenta-bioworks-tff-pharmaceuticals-announce-120000897.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.